Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease
Aachen, Germany / Pittsburgh, PA, USA (ots) - - The acquisition supports Grünenthal's commercial and R&D strategy to drive innovation in pain. - Thar Pharmaceutical's lead compound, T121, complements Grünenthal's existing development pipeline and the goal of delivering innovative and effective treatments to ...
mehr